Lucid Diagnostics reports Q3 EPS (10c), consensus (9c)

Reports Q3 revenue $1.2M, consensus $1.35M. Lucid had cash and cash equivalents of $47.3M as of September 30, compared to $22.4M as of December 31, 2024. “The overwhelmingly positive MolDx CAC meeting in September-with medical experts unanimously supporting Medicare coverage for EsoGuard-further reinforces our confidence that we are now firmly in the final stages of achieving this transformative coverage milestone,” said Lishan Aklog, Lucid’s Chairman and CEO. “Our strengthened balance sheet, continued commercial execution, targeted initiatives aimed at the Medicare population, and a new world-class market access team driving payor engagement have us well-prepared to accelerate EsoGuard commercialization as Medicare coverage and other upcoming reimbursement milestones are secured.”